Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology
Reference13 articles.
1. Theophylline: new perspectives for an old drug;Barnes;Am J Respir Crit Care Med,2003
2. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease;Lipworth;Lancet,2005
3. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions;van Schalkwyk;J Allergy Clin Immunol,2005
4. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo;Timmer;J Clin Pharmacol,2002
5. Efficacy and safety of roflumilast in the treatment of asthma;Bateman;Ann Allergy Asthma Immunol,2005
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of roflumilast on airway remodelling in a murine model of chronic asthma;Clinical & Experimental Allergy;2016-04-26
2. Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia;Targets and Emerging Therapies for Schizophrenia;2012-06-24
3. Targeting Allergic Airway Diseases by siRNA: An Option for the Future?;Current Molecular Medicine;2009-05-01
4. Use of Theophylline and Sodium Cromoglycate in Adult Asthma;Allergy Frontiers: Therapy and Prevention;2009
5. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma;Expert Opinion on Investigational Drugs;2008-04-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3